Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-09-29
1999-08-17
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142355, 514414, 514415, 514443, A61K 3144, A61K 31535, A61K 3140, A61K 31405, A61K 3138
Patent
active
059394293
ABSTRACT:
Hemorrhagic shock and in other conditions associated with excessive vasoconstriction, such as hypertension, peripheral vascular disease, cirrhosis of the liver, or certain forms of angina pectoris can be treated by using agonists of CB1 receptors as well as other cannabinoid receptors. In addition, it has been determined that in septic shock and cirrhosis of the liver when hypotension is due to activation of macrophages by bacterial endotoxin, the use of a drug that selectively blocks CB1 receptors or other cannabinoid receptors may be of therapeutic value by preventing or attenuating the endotoxin-induced hypotension.
REFERENCES:
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5605906 (1997-02-01), Lau
patent: 5747524 (1998-05-01), Cullinan et al.
Ellis Earl F.
Kunos George
Sanyal Aron
Varga Karoly
Wagner Jens
Henley III Raymond
Virginia Commonwealth University
LandOfFree
Cardiovascular uses of cannabinoid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiovascular uses of cannabinoid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiovascular uses of cannabinoid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-315022